Akebia Therapeutics, Inc. AKBA 深 滬
等待開盤 03-26 09:30:00 美东时间
1.39
+0.030
+2.21%
華盛通- 最 高1.415
- 今 開1.40
- 成交量 188.53万股
- 最 低 1.3618
- 昨 收 1.36
- 總市值 3.72亿
- 52周最高 4.0787
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.14
- 委 比 4.79%
- 總股本 2.68亿
- 歷史最高 31.00
- 量 比 0.56
- 振 幅 3.91%
- 歷史最低 0.241
- 每 手 1
- 風險率 0.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
Akebia Therapeutics announced a virtual R&D Day on April 2, 2026, featuring experts discussing its kidney disease pipeline: Praliciguat (Phase 2 for FSGS), AKB-097 (Phase 2 basket trial for rare kidney diseases), and AKB-9090 (Phase 1 for AKI). Registration and details available via the provided link.
03-19 20:05
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -...
03-10 18:59
Akebia Therapeutics to Present at Leerink Partners Global Healthcare Conference
Akebia Therapeutics to Present at Leerink Partners Global Healthcare Conference Akebia Therapeutics Inc. said CEO John P. Butler and CFO/CBO Erik Ostrowski will take part in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026 at 8:00 a.m. ET in Miami. A webcast
03-03 21:02
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
Akebia Therapeutics, Inc. announced that CEO John P. Butler and CFO/Chief Business Officer Erik Ostrowski will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on March 9 at 8:00 AM ET in Miami. A webcast will be available on Akebia’s investor website.
03-03 13:00
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics granted stock options to five new employees on February 27, 2026, allowing them to purchase a total of 46,200 shares at $1.31 per share, the closing price on the grant date. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly, contingent on continued employment. Each option has a 10-year term and adheres to Nasdaq Listing Rule 5635(c)(4) and the company's induceme...
03-02 21:05
Akebia Therapeutics Q4 EPS $(0.05) Misses $(0.03) Estimate, Sales $57.620M Beat $48.373M Estimate.
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 85.19 percent. This is a 50 percent increase over losses of $(0.10) per share
02-26 20:04
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
<p>CAMBRIDGE, Mass., Feb. 19, 2026 – Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced it will release its fourth-quarter and full-year 2025 financial results on February 26, 2026, before U.S. markets open. The company will host a conference call on February 26 at 8:00 a.m. EST to discuss its financial results and recent business highlights. Registrants can access dial-in details via the provided Registration Link. A live webcast will be availab...
02-19 13:00
Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
Akebia Therapeutics ($AKBA) announced an update on their ongoing clinical study...
02-11 00:30
